Document is current
Any future updates will be listed below
-
Authors
Smart, Alicia C.
Goyal, Lipika
Horick, Nora
Petkovska, Natasa
Zhu, Andrew X.
Ferrone, Cristina R.
Tanabe, Kenneth K.
Allen, Jill N.
Drapek, Lorraine C.
Qadan, Motaz
Murphy, Janet E.
Eyler, Christine E.
Ryan, David P.
Hong, Theodore S.
Wo, Jennifer Y.
-
Funding
Funding for this research was provided by:
DF/HCC SPORE in Gastrointestinal Cancer (2P50CA127003-08)
NIH Rare Cancer Genetics Registry (4R01CA160233-05)
- License Information
-
More Information
Article History
Received: 20 July 2019
First Online: 23 December 2019
Disclosures
: Theodore S. Hong receives research/clinical trial support from Astra-Zeneca, BMS, Novartis, IntraOp, and Taiho, and serves on an advisory board for Merck. Motaz Qadan receives consulting fees from Olympus. David P. Ryan discloses the following financial relationships: Equity: MPM Capital, Acworth Pharmaceuticals; Advisory: MPM Capital, Oncorus, Gritstone Oncology, Maverick Therapeutics, 28/7 Therapeutics; Publishing: Johns Hopkins University Press, Uptodate, McGraw Hill. Kenneth K. Tanabe receives royalties as an editor of Uptodate. Andrew X. Zhu provides consulting and advisory services for Bayer, BMS, Eisai, Merck, Novartis, Sanofi, Mina, C-Stone, Lilly, Roche/Genentech, and Incyte.
